Involved in various multicenter clinical trials with new anti-fibrotic agents for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Our Interstitial Lung Disease Group and Clinic has been selected by the NIH to participate in the IPF Network investigational studies.
RESEARCH INTERESTS
Pulmonary Fibrosis
Bronchiolitis
Venous Thromboembolic Disease
RECENT PUBLICATIONS
Girod C.E. and M.I. Schwarz, "Other Large-Airway Diseases that Limit Airflow." In: Chronic Obstructive Lung Diseases. N.F. Voelkel and W. MacNee, editors, 1st ed., B.C. Decker, Inc., Hamilton, Ontario, Chapter 14 / 2nd. Ed. December 2007
Girod CE and Schwarz MI, "Diffuse Interstitial Lung Diseases Resulting in Airflow Limitation" Chronic Obstructive Lung Diseases. Editors N.F. Voelkel and W. MacNee, 2nd. ed., Second Edition December 2007
Girod C.E. and King T.E., "Opinions and Hypothesis: Emphysema: A chronic dust-induced disease?" CHEST, 128; Number 4:3055-3064, October 2005
SIGNIFICANT PUBLICATIONS
Robert L.K., Y.E. Miller, T.M. Hudish, C.E. Girod, S. Sotto-Santiago, W.A. Franklin, R.A. Nemenoff, T.H. March, S.P. Nana-Sinkam, and M.W. Geraci, "Pulmonary prostacyclin synthase overexpression chemoprevents tobacco smoke lung carcinogenesis in mice." Cancer Research, 64:5897-5904, 2004
Girod C.E., "Thrombolytic therapy in massive and sub-massive pulmonary embolism." PCCU (Pulmonary and Critical Care Update) Online, ACCP, Volume 14, Lesson 19 December 2000
Point and right click (click and hold for Mac users) your mouse onand select "Save this link (or target) as..." option to save the file to your local computer.